Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef

Journal of Infectious Diseases

Volumn 192, Issue 5, 2005, Pages 749-759

  Thakar, Madhuri R ^a,c   Bhonge, Leena S ^a   Lakhashe, Samir K ^a   Shankarkumar, U ^b   Sane, Suvarna S ^a   Kulkarni, Smita S ^a   Mahajan, Bharati A ^a   Paranjape, Ramesh S ^a  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

^b NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

^c Maharashtra Industrial Development Corporation India   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN;

ADULT; AFRICA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIAN; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, NEF; HIV INFECTIONS; HIV-1; HUMANS; IMMUNODOMINANT EPITOPES; INDIA; INTERFERON TYPE II; MALE; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 23944486745     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/432547     Document Type: Article

References (47)

1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-10.
2. Dalod M, Dupuis M, Deschemin IC, et al. Broad, intense anti human immunodeficiency virus (HIV) ex vivo CD8+ responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol 1999; 73:7108-16.
3. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181:1365-72.
4. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001; 410:980-7.
5. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279:2103-6.
6. Ogg GS, Kostense S, Klein MR, et al. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. J Virol 1999; 73:9153-60.
7. Cao J, McNevin J, Holte S, Fink L, Corey L, McElrath MJ. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 2003; 77:6867-78.
8. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable non-progressing HIV type 1 infection. AIDS Res Hum Retrovir 1996; 12: 585-92.
9. Barouch DH, Craiu A, Santra S, et al. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and sub-dominant simian human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J Virol 2001; 75:2462-7.
10. mac-induced immunodeficiency. J Virol 2002; 76:292-302.
11. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8 T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189:991-8.
12. Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet 2000; 355:2061-6.
13. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001; 19:4652-60.
14. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997; 94:1396-401.
15. Keating SM, Bollinger RC, Quinn TC, Jackson JB, Carruth LM. Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays. AIDS Res Hum Retroviruses 2002; 18:1067-79.
16. Addo M, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77: 2081-92.
17. De Groot AS, Jesdale B, Martin W, et al. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatic approach. Vaccine 2003; 21: 4486-504.
18. Dorrell L, Dong T, Ogg GS, et al. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J Virol 1999; 73: 1708-14.
19. + lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001; 107:1303-10.
20. Novitsky V, Rybak N, McLane MF, et al. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific Elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 2001; 75:9210-28.
21. Thakar M, Patke D, Lakhashe S, et al. Consistent subtype-specific anti-HIV-1 immune responses associated with lower plasma viral load in early HIV infection. AIDS Res Hum Retroviruses 2002; 18:1389-93.
22. Masemola A, Mashishi T, Khoury G, et al. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol 2004; 78:3233-43.
23. Novitsky V, Cao H, Rybak N, et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 2002; 76:10155-68.
24. Gadkari DA, Moore D, Sheppard HW, Mehendale SM, Kulkarni S, Bollinger RC. Transmission of genetically diverse strains of HIV-1 in India. Indian J Med Res 1998; 107:1-9.
25. Eshleman SH, Hudelson SE, Gupta A, et al. Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India. AIDS Res Hum Retroviruses 2005; 21:93-7.
26. Shankarkumar U, Ghosh K, Mohanty D. Defining the allelic variants of HLA A19 in the Western Indian population. Hum Immunol 2002; 63:779-82.
27. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152:163-75.
28. Day CL, Shea AK, Altfeld MA, et al. Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. J Virol 2001; 75:6279-91.
29. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. Magnitude of functional CD8+ T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002; 76:2298-305.
30. Alter G, Merchant A, Tsoukas C, et al. Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection. J Infect Dis 2002; 185:755-65.
31. Paranjape RS, Gadkari DA, Lubaki M, Quinn TC, Bollinger RC. Cross-reactive HIV-1-specific CTL in recent seroconverters from Pune, India. Indian J Med Res 1998; 108:35-41.
32. Carmichael A, Jin X, Sissons P. Analysis of the human Env cytotoxic T-lymphocyte (CTL) response in natural immunodeficiency virus type 1 infection: low prevalence of broadly cross-reactive Env-specific CTL. J Virol 1996; 70:8468-76.
33. Durali D, Morvan J, Letourneur F, et al. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J Virol 1998; 72:3547-53.
34. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5.
35. Van Baalen CA, Pontesilli O, Huisman RC, et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78:1913-8.
36. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:11983-91.
37. Gea-Banacloche JC, Migueles SA, Martino L, et al. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 2000; 165:1082-92.
38. CTL epitope summary: HIV molecular immunology database. In: Korber B, Brander C, Haynes B, et al., eds. HIV molecular immunology 2000. Los Alamos, NM: Los Alamos National Laboratory, Theoretical Biology and Biophysics, 2000. Available at: http://www.hiv.lanl.gov/ content/immunology/contents2000.html. Accessed 26 March 2005.
39. Culmann B, Gomard E, Kieny MP, et al. Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of HIV-1 Nef protein. J Immunol 1991; 146:1560-5.
40. Mashishi T, Loubser S, Hide W, et al. Conserved domains of subtype C Nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. AIDS Res Hum Retroviruses 2001; 17:1681-7.
41. Umapathy S, Thakar M, Mehendale S, Praranjape RS, Mohanty D. Association of HLA B*3520, B*1801 and Cw*1507 with HIV-1 infection in Maharashtra, India. J Acquir Immune Defic Syndr 2003; 34:113-4.
42. Bertoni R, Sidney J, Fowier P, Chesnut R, Chisari F, Sette A. Human histocompatibility leukocyte antigen-binding super motifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest 1997; 100:503-13.
43. WHO-UNAIDS Vaccine Advisory Committee. Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1. Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee, Geneva, 21-23 February 2000. AIDS 2001; 15:W1-25.
44. Evans DT, O'Connor DH, Jing P, et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med 1999; 5:127-6.
45. Goulder PJ, Bunce M, Krausa P, et al. Novel cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses 1996; 12:1691-8.
46. Brander C, Goulder PJ. The evolving field of HIV CTL epitope mapping: new approaches to the identification of novel epitopes. In: Korber B, Brander C, Haynes B, et al., eds. HIV molecular immunology 2000. Los Alamos, NM: Los Alamos National Laboratory, Theoretical Biology and Biophysics, 2000. Available at: http://www.hiv.lanl.gov/content/ immunology/pdf/2000/1/Brander.pdf. Accessed 26 March 2005.
47. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3:205-11.